FATE THERAPEUTICS INC business relationships
Companies named in FATE THERAPEUTICS INC’s 10-K filed 2026-02-26, and public companies whose annual reports name FATE THERAPEUTICS INC. Each link shows the sentence it came from. Scores are Engagemii’s AI visibility scores.
- AEO visibility
- 5.5 / 10
- AI naming
- 92 / 100 Top 1% in its category
- Agent readiness
- 0 / 100
- AI adoption
- 0 / 100
Named in FATE THERAPEUTICS INC’s annual report 2
“License Agreement, dated April 9, 2020, by and between the Registrant and Dana-Farber Cancer Institute, Inc.” SEC filing
“In August 2019, we entered into a license agreement with Inscripta, Inc. Under the license agreement, we obtained a royalty-free, irrevocable license to a patent portfolio covering the composition, production and use of MAD7, a novel gene-editing CRISPR endonuclease from the Eubacterium rectale geno...” SEC filing
Links are read automatically from SEC annual reports (10-K, 20-F, 40-F). In a hand check of random links, about 8 in 10 were real business relationships, so every link carries its source sentence.